Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Howell MichaelOwnership Type:Indirect OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:7,987Price:$3.13
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Nistala KiranOwnership Type:Direct OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,195Price:$3.13
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Munshi AmitOwnership Type:Direct OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:159,744Price:$3.13
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Sidhu SomeitOwnership Type:Indirect OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,186,901Price:$3.13
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Lisicki RobertOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,000,000Price:--
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Ploos van Amstel ArnoutOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,149Price:--
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Thiara ParvinderOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,149Price:--
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Nistala KiranOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:350,000Price:--
-
Dec 12, 2023 (filed on Dec 14, 2023)Insider Name:Thiara ParvinderOwnership Type:Indirect OwnershipSecurities:Class A Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,000,000Price:$4.00
-
Dec 11, 2023 (filed on Dec 13, 2023)Insider Name:Sidhu SomeitOwnership Type:Direct OwnershipSecurities:WarrantsNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,750,000Price:--
Filings by filing date
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Howell MichaelOwnership Type:Indirect OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:7,987Price:$3.13
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Nistala KiranOwnership Type:Direct OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,195Price:$3.13
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Munshi AmitOwnership Type:Direct OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:159,744Price:$3.13
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Sidhu SomeitOwnership Type:Indirect OwnershipSecurities:Class A ordinary sharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,186,901Price:$3.13
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Lisicki RobertOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,000,000Price:--
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Ploos van Amstel ArnoutOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,149Price:--
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Thiara ParvinderOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:48,149Price:--
-
Jan 24, 2024 (filed on Jan 26, 2024)Insider Name:Nistala KiranOwnership Type:Direct OwnershipSecurities:Stock optionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:350,000Price:--
-
Dec 12, 2023 (filed on Dec 14, 2023)Insider Name:Thiara ParvinderOwnership Type:Indirect OwnershipSecurities:Class A Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,000,000Price:$4.00
-
Dec 11, 2023 (filed on Dec 13, 2023)Insider Name:Sidhu SomeitOwnership Type:Direct OwnershipSecurities:WarrantsNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,750,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4225 Executive Square, Suite - 600 SAN DIEGO CA 92037 |
Tel: | N/A |
Website: | https://zurabio.com |
IR: | See website |
Key People | ||
Robert Lisicki Chief Executive Officer, Director | Verender S. Badial Interim Chief Financial Officer | Theresa Lowry Chief Human Resource Officer |
Gary Whale Chief Technology Officer | Michael Howell Chief Scientific Officer, Head of Translational Medicine | Kiran Nistala Chief Medical Officer, Head of Development | Kim Davis Chief Legal Officer and Secretary |
Business Overview |
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation. |
Financial Overview |
For the fiscal year ended 31 December 2023, Zura Bio Ltd revenues was not reported. Net loss applicable to common stockholders totaled $69.2M vs. income of $3.5M. Net loss reflects Change in fair value of derivative decrease of 83% to $724K (income), Income from investments held in Trust decrease of 33% to $1.4M (income). Basic Earnings per Share excluding Extraordinary Items decreased from $0.21 to -$2.09. |
Employees: | 14 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $196.68M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$62.64M as of Dec 31, 2023 |
Net annual income (TTM): | -$69.24M as of Dec 31, 2023 |
Free cash flow (TTM): | -$17.30M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 63,683,806 as of Apr 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |